Margaret A.WinkerMDIndividualAuthorPhil B.FontanarosaMD, Senior EditorsIndividualAuthor
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
To the Editor.—Although the publication of guidelines1 has provided an important contribution to standardizing cost-effectiveness (CE) research, some methodological points still need clarification. In comparing treatment A (innovative treatment) with treatment B (reference treatment), a CE analysis is appropriate when A is more effective, ie, when the difference in clinical effectiveness between A and B is significant.
Trippoli S, Messori A. Cost-effectiveness Analyses of Statistically Ineffective Treatments. JAMA. 1998;280(23):1992-1993. doi:10-1001/pubs.JAMA-ISSN-0098-7484-280-23-jbk1216